Introduction
Tumor angiogenesis involves the formation of new blood vessels from pre-existing blood vessels [1] . When solid tumors reach around 2 mm in diameter, they can no longer obtain sufficient nutrients and oxygen simply by diffusion from their surrounding environments. To trigger tumor angiogenesis, tumor cells secrete high levels of several important pro-angiogenic factors, including vascular endothelial growth factor-A (VEGF-A), placental growth factor (PIGF) and basic fibroblast growth factor (bFGF), into the tumor microenvironment [2] . These factors collectively activate quiescent endothelial cells of the surrounding blood vessels, which in turn promote endothelial cell proliferation, migration and tube formation via the regulation of cell adhesion molecules, such as integrins [3] . As angiogenesis is an important rate-limiting step in tumor growth, anti-angiogenesis therapy was conceived as a golden opportunity for cancer treatment [4] . It is clear that, in combination with chemotherapies, anti-angiogenic drugs (which reduce blood vessel numbers in the tumor) can provide advantages, although anti-angiogenic monotherapy is less effective [5] . For example, treatment of advanced colorectal cancer with anti-angiogenesis drugs in combination with chemotherapy can have significant survival benefits [6] . In contrast to these promising results, anti-angiogenic agents in combination with chemotherapy have consistently failed to improve overall survival for other types of cancer, including breast, pancreatic and prostate [7] . The lack of anti-angiogenic monotherapy efficacy may be due to the development of intrinsic or acquired resistance to therapy [8] . Moreover, although not proven clinically, preclinical data indicate that decreasing the tumor's blood supply results in hypoxia, possibly fueling tumor progression and metastasis [9, 10] .
As an alternative to anti-angiogenesis therapy, a different approach to improve blood vessel functionality has been suggested, namely vascular normalization. This strategy often involves partially reducing blood vessel numbers in tumors, whilst allowing better-functioning vessels with improved pericyte coverage and a more intact basement membrane. These vessels are less tortuous and allow for improved blood flow and reduced tumor hypoxia. Thus, in combination with chemotherapy, such vascular normalization strategies can improve drug delivery and cancer growth control [11, 12] . For example, when the antiangiogenesis drug bevacizumab is used at lower doses, it can transiently 'normalize' tumor blood vessels and partially reduce blood vessel density, resulting in an increase in tumor perfusion and providing a therapeutic window for better chemotherapeutic drug delivery [12] . Many anti-angiogenic drugs such as sorafenib and sunitinib have also been shown to act as potential normalizing agents in both preclinical and clinical models, with the functionality of tumor blood vessels being significantly improved in some cases [13, 14] . Overall, however, this approach is dose and context dependent. For instance, the dose of anti-VEGF drugs needs to be adjusted relative to the level of VEGF in tumors during treatment, over time, in order to achieve an optimal balance between pro-angiogenic and anti-angiogenic factors for vessel normalization to occur. Like anti-angiogenic monotherapy, it is challenging to identify the agents and biomarkers that can be used in the clinic to provide and predict precise vessel normalization effects [15] . For comprehensive reviews of anti-angiogenesis and blood vessel normalization, please see Jain [11] and Kerbel [16] .
In this review, we will discuss the current progress of anti-angiogenesis and vascular normalization approaches, and how we have learnt from them to develop an alternative therapeutic strategy for targeting the tumor vasculature that involves vascular promotion.
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